SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Welcome to the POTP board, the DPP-IV company
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: keokalani'nui who wrote (3)7/21/2006 9:50:38 PM
From: rareearth42  Read Replies (1) of 90
 
Wilder,

I don't know any more about which NSCLC patients had the CRs, sorry. To my mind, since they had failed cisplatin as an enrollment requirement and the likelihood of a CR at that point is really low, it was a terrific result regardless.

Regarding GENT, if it falls much more, I'm going to start buying again. The studies being done in the US are for VOD treatment, but they're doing prevention trials in Europe. I think they'll both work. The street doesn't know the company or VOD yet, but when the phase 3 trials are successful with a mortality benefit, the run-of-the-mill analysts will start paying attention and the company's value will increase substantially.

RE42
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News